Volume 8, Number 10—October 2002
First Case of Bioterrorism-Related Inhalational Anthrax, Florida, 2001: North Carolina Investigation
|Type of surveillance||Targeted population or outcome||Locations under surveillance|
|Intensive-care unit||Patients with illness compatible with systemic anthrax infectiona||19 hospitals in North and South Carolinab|
|Microbiology laboratory||Bacterial isolates potentially consistent with Bacillus anthracisc||19 hospitals in North and South Carolina|
|Medical examiner||Unexplained deaths possibly due to anthrax infection||Statewide|
|Veterinarian||Unexplained deaths in livestock||Statewide|
|Occupational||Unexplained illnesses or absences in employees||Tourist park visited by the index patient|
|Environmental||Evidence of B. anthracis spores||Residence of index patient’s relative; tourist park visited by the index patient|
aClinical syndromes included fever and 1) severe respiratory disease, 2) mediastinitis or mediastinal lymphadenitis, 3) meningitis, or 4) hemorrhagic gastroenteritis.
bBased on the index patient’s route of travel, surveillance occurred in all 15 hospitals with intensive-care units in five North Carolina counties, as well as four regional referral centers in North Carolina (n=2) and South Carolina (n=2).
cA suspicious isolate was defined as 1) nontyped Bacillus species, 2) unidentified nonhemolytic, nonmotile gram-positive rod, or 3) any other unidentified bacteria that was discarded or sent to a referral laboratory.
- Page created: July 19, 2010
- Page last updated: July 19, 2010
- Page last reviewed: July 19, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)